For research use only. Not for use in humans.

Burosumab (Anti-FGF23)

Synonyms: KRN23

Burosumab (Anti-FGF23) is a neutralising antibody, targeting human fibroblast growth factor 23 (FGF23). It can be used for the research of X-linked hypophosphatemia (XLH) and tumour-induced osteomalacia. MW: 145.5 KD.

Burosumab (Anti-FGF23)

Quality Control

Batch: A249901 Purity: 99% Protein concentration: 5.19mg/ml Endotoxin Level: <1EU/mg
99

Specificity

Name Citation FGFR1 FGFR2 FGFR3 FGFR4 Others
PD173074 124 VEGFR2
Dovitinib (TKI-258) 52 FLT3,c-Kit,VEGFR3/FLT4
AZD4547 (Fexagratinib) 145 KDR
Danusertib (PHA-739358) 46 Aurora A,Abl,TrkA
Brivanib (BMS-540215) 10 VEGFR2,Flk1,VEGFR1
MK-2461 4 c-Met (M1250T),c-Met (Y1235D),c-Met (Y1230H)
Brivanib Alaninate (BMS-582664) 2 VEGFR2,Flk1,VEGFR1
SSR128129E 9
H3B-6527 12
PRN1371 2 CSF1R
PD-166866 15
Fisogatinib (BLU-554) 10
S49076 1 Met,Mer,Axl
SU 5402 24 VEGFR2,PDGFRβ
BLU9931 21
FIIN-2 5
Dovitinib (TKI258) Lactate monohydrate 31 FLT3,c-Kit,VEGFR3/FLT4
Zoligratinib (Debio-1347) 12
LY2874455 15 VEGFR2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Burosumab (Anti-FGF23) is a neutralising antibody, targeting human fibroblast growth factor 23 (FGF23). It can be used for the research of X-linked hypophosphatemia (XLH) and tumour-induced osteomalacia. MW: 145.5 KD.

Product Details

CAS No. 1610833-03-8
Molecular Weight 144 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Sellecks selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.